NCT00004654View on ClinicalTrials.gov

Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 1996

Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
DRUG

soy protein isolate

All Listed Sponsors
collaborator

Yale University

OTHER

lead

National Center for Research Resources (NCRR)

NIH

NCT00004654 - Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia | Biotech Hunter | Biotech Hunter